George Tidmarsh, director of the FDA's Center for Drug Evaluation and Research (CDER), signaled a review of the agency's use of surrogate endpoints for drug approval. These endpoints, which rely on indirect measures rather than clinical outcomes, have accelerated drug approvals but raised debate about their clinical relevance and safety. Tidmarsh’s scrutiny highlights the FDA's ongoing efforts to balance faster access to therapies with assurance of meaningful patient benefits.